146 related articles for article (PubMed ID: 15994148)
1. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.
Czuczman MS; Thall A; Witzig TE; Vose JM; Younes A; Emmanouilides C; Miller TP; Moore JO; Leonard JP; Gordon LI; Sweetenham J; Alkuzweny B; Finucane DM; Leigh BR
J Clin Oncol; 2005 Jul; 23(19):4390-8. PubMed ID: 15994148
[TBL] [Abstract][Full Text] [Related]
2. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.
Leonard JP; Friedberg JW; Younes A; Fisher D; Gordon LI; Moore J; Czuczman M; Miller T; Stiff P; Cheson BD; Forero-Torres A; Chieffo N; McKinney B; Finucane D; Molina A
Ann Oncol; 2007 Jul; 18(7):1216-23. PubMed ID: 17470451
[TBL] [Abstract][Full Text] [Related]
3. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
Leonard JP; Coleman M; Ketas JC; Chadburn A; Furman R; Schuster MW; Feldman EJ; Ashe M; Schuster SJ; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Fields SZ; Cesano A; Goldenberg DM
Clin Cancer Res; 2004 Aug; 10(16):5327-34. PubMed ID: 15328168
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
Advani A; Coiffier B; Czuczman MS; Dreyling M; Foran J; Gine E; Gisselbrecht C; Ketterer N; Nasta S; Rohatiner A; Schmidt-Wolf IG; Schuler M; Sierra J; Smith MR; Verhoef G; Winter JN; Boni J; Vandendries E; Shapiro M; Fayad L
J Clin Oncol; 2010 Apr; 28(12):2085-93. PubMed ID: 20308665
[TBL] [Abstract][Full Text] [Related]
5. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
Advani R; Forero-Torres A; Furman RR; Rosenblatt JD; Younes A; Ren H; Harrop K; Whiting N; Drachman JG
J Clin Oncol; 2009 Sep; 27(26):4371-7. PubMed ID: 19636010
[TBL] [Abstract][Full Text] [Related]
8. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
de Vos S; Goy A; Dakhil SR; Saleh MN; McLaughlin P; Belt R; Flowers CR; Knapp M; Hart L; Patel-Donnelly D; Glenn M; Gregory SA; Holladay C; Zhang T; Boral AL
J Clin Oncol; 2009 Oct; 27(30):5023-30. PubMed ID: 19770386
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas JC; Chadburn A; Ely S; Furman RR; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Cesano A; Goldenberg DM
J Clin Oncol; 2003 Aug; 21(16):3051-9. PubMed ID: 12837807
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma.
Tobinai K; Ogura M; Kobayashi Y; Uchida T; Watanabe T; Oyama T; Maruyama D; Suzuki T; Mori M; Kasai M; Cronier D; Wooldridge JE; Koshiji M
Cancer Sci; 2011 Feb; 102(2):432-8. PubMed ID: 21205069
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
12. The use of galiximab in non-Hodgkin lymphoma.
Vinjamaram S; Czuczman MS; Hernandez-Ilizaliturri FJ
Clin Lymphoma Myeloma; 2008 Oct; 8(5):277-82. PubMed ID: 18854281
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.
Gottlieb AB; Kang S; Linden KG; Lebwohl M; Menter A; Abdulghani AA; Goldfarb M; Chieffo N; Totoritis MC
Clin Immunol; 2004 Apr; 111(1):28-37. PubMed ID: 15093549
[TBL] [Abstract][Full Text] [Related]
14. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
Friedberg JW; Cohen P; Chen L; Robinson KS; Forero-Torres A; La Casce AS; Fayad LE; Bessudo A; Camacho ES; Williams ME; van der Jagt RH; Oliver JW; Cheson BD
J Clin Oncol; 2008 Jan; 26(2):204-10. PubMed ID: 18182663
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
[TBL] [Abstract][Full Text] [Related]
18. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S; Dührsen U; Nückel H
Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
Strauss SJ; Morschhauser F; Rech J; Repp R; Solal-Celigny P; Zinzani PL; Engert A; Coiffier B; Hoelzer DF; Wegener WA; Teoh NK; Goldenberg DM; Lister TA
J Clin Oncol; 2006 Aug; 24(24):3880-6. PubMed ID: 16864854
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A
J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
